Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: A tissue microarray-based study

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 4, 2007, Pages 556-562

  Bhardwaj, Atul ^a,d   Marsh Jr , William L ^a   Nash, Jason W ^b   Barbacioru, Catalin C ^c   Jones, Susie ^a   Frankel, Wendy L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c APPLIED BIOSYSTEMS   (United States)

^d Pinnacle Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MASPIN; MUCIN 4; PROTEIN P53; SMAD4 PROTEIN;

ADULT; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MUCINS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; SENSITIVITY AND SPECIFICITY; SERPINS; SMAD4 PROTEIN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147166570     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Maass N, Hojo T, Ueding M, et al. Expression of the tumor suppressor gene maspin in human pancreatic cancers. Clin Cancer Res. 2001;7:812-817.
2. Fitzgerald M, Oshiro M, Holtan N, et al. Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia. 2003;5:427-436.
3. Oh YL, Song SY, Ahn C. Expression of maspin in pancreatic neoplasms: application of maspin immuno-histochemistry to the differential diagnosis. Appl Immunohistochem Mol Morphol. 2002;10:62-66.
4. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7:4033-4040.
5. Swartz MJ, Batra SK, Varshney CC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002;117:791-796.
6. Balague C, Gambus C, Carrato C, et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology. 1994;106:1054-1061.
7. Balague C, Audie JP, Porchet N, Real FX. In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology. 1995;109:953-964.
8. Moore PS, Beghelli S, Zamboni C, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer. 2003;2:7-12.
9. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-1734.
10. Moore PS, Orlandini S, Zamboni C, et al. Pancreatic tumors: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorogenesis. Br J Cancer. 2001;84:253-262.
11. Hua Z, Zhang YC, Hu XM, Jia ZC. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol. 2003;9:2764-2767.
12. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-43.
13. Tascilar M, Skinner HC, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115-4121.
14. Chen XL, Zhang QH, Ni QX. The relationship between tumor suppressor genes p14ARF and p53 expression and biological behavior of pancreatic carcinoma [in Chinese]. Zhonghua Yi Xue Za Zhi. 2003;83:868-871.
15. Gu LJ, Chen J, Lu ZH, Li L, Zhou WX, Luo YF. Expression of DPC4/Smad4, p21wafl, and p16 in human pancreatic cancer [in Chinese]. Ai Zheng. 2002;21:132-137.
16. Biankin AV, Kench JG, Biankin SA, et al. Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol. 2004;28:1184-1192.
17. Gazzaniga GM, Papadia FS, Dezzana M, Cappato S, Filauro M, Bandelloni R. Role of p53 mutations on survival after pancreatodudenectomy for ductal adenocarcinoma of pancreatic head. Hepatogastroenterology. 2001;48:1743-1745.
18. Sessa F, Bonato M, Bisoni D, Ranzani CN, Capella C. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship between phenotype and survival. Eur J Histochem. 1998;42:67-76.
19. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997;47:813-830.
20. Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002;9:328-341.
21. Kloppel C, Hruban RH, Longnecker DS, Adler C, Kern SE, Partanen TJ. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:221-230. World Health Organization Classification of Tumours.
22. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994;263:526-529.
23. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA. 1996;93:11669-11674.
24. Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer. 2002;3:281-287.
25. Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol. 2003;169:1157-1161.
26. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23:1531-1538.
27. Ohike N, Maass N, Mundhenke C, et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett. 2003;199:193-200.
28. Nash JW, Bhardwaj A, Wen P, Frankel WL. Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl Immunohist Mol Morphol. 2006. In press.
29. Shibahara H, Tamada S, Higashi M, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004;39:222-229.
30. Komatsu M, Tatum L, Altman NH, Carothers Carraway CA, Carraway KL. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int J Cancer. 2000;87:480-486.
31. Ciccarelli FD, Doerks T, Bork P. AMOP, a protein module alternatively spliced in cancer cells. Trends Biochem Sci. 2002;27:113-115.
32. Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines, Int J Cancer. 1994;57:198-203.
33. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res. 2002;8:2563-2569.
34. Sears D, Erickson RA, Sayage-Rabie L, Escobar MC. TCP-beta and p53 staining in CT guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma. Dig Dis Sci. 2004;49:828-832.
35. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Crody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30:123-129.
36. de vos tot Nederveen Cappel WH, Offerhaus GJ, van Puijenbroek M, et al. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clin Cancer Res. 2003;9:3598-3605.
37. Hahn SA, Schutte M, Hoque A, et al. DPC4, a candidate tumor suppressor gene at 18q21.1. Science. 1996;271:350-353.
38. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA. 2000;97:9624-9629.
39. Xu J, Attissano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 2000;97:7820-7825.
40. McCarthy DM, Hruban RH, Argani P, et al. Role of DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases. Mod Pathol. 2003;16:272-278.
41. Sasaki S, Yamamoto H, Kaneto H, et al. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep. 2003;10:21-25.
42. Lim YJ, Lee JK, Jang WY, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma. Korean J Intern Med. 2004;19:15-18.